ライフサイエンスコーパス: stem cell transplant

1 sion-free without a consolidative allogeneic stem cell transplant.

2 tezomib treatment and high-dose melphalan in stem cell transplant.

3 and mortality after allogeneic hematopoietic stem cell transplant.

4 and mortality after allogeneic hematopoietic stem cell transplant.

5 olidation in first remission with autologous stem cell transplant.

6 tivation is a significant complication after stem cell transplant.

7 35 (53%) to lenalidomide; 39 (59%) had prior stem cell transplant.

8 ith one of these viruses after hematopoietic stem cell transplant.

9 p select appropriate patients for allogeneic stem cell transplant.

10 ections occur frequently after hematopoietic stem cell transplant.

11 ole without recurrence after a hematopoietic stem cell transplant.

12 utility and convenience of peripheral blood stem cell transplant.

13 se of pneumonia following a peripheral blood stem cell transplant.

14 rom a patient who had received an allogeneic stem cell transplant.

15 nors for patients in need of a hematopoietic stem cell transplant.

16 mia treatment that included an HIV-resistant stem cell transplant.

17 latinum-based chemotherapy before autologous stem cell transplant.

18 4 consecutive patients undergoing allogeneic stem cell transplant.

19 opoietic progenitor cells in preparation for stem cell transplant.

20 the development of allogeneic hematopoietic stem cell transplant.

21 0(9) engineered T cells 2 d after autologous stem cell transplant.

22 titution after unrelated-donor hematopoietic stem cell transplant.

23 Hodgkin lymphoma received chemotherapy and a stem cell transplant.

24 ailed to identify an etiology, 6 weeks after stem cell transplant.

25 py, prior methotrexate, and prior autologous stem-cell transplant.

26 atments (range 1-11); 18 (38%) had undergone stem-cell transplant.

27 6 responses among the 18 patients with prior stem-cell transplant.

28 ease (>/=10(-4) cells) received an allogenic stem-cell transplant.

29 ho were not planned for immediate autologous stem-cell transplant.

30 tological malignancies and the recipients of stem-cell transplant.

31 enance treatment or autologous or allogeneic stem-cell transplant.

32 iduals, particularly those who have received stem cell transplants.

33 osuppressive therapies and/or solid organ or stem cell transplants.

34 rance to both solid organ and haematopoietic stem cell transplants.

35 has become the preferred source of HSPCs for stem cell transplants.

36 oxantrone, or with autologous haematopoeitic stem cell transplants.

37 t on to receive high-dose therapy and tandem stem cell transplants.

38 igh-dose therapy, with or without autologous stem cell transplants.

39 versus host disease in matched or mismatched stem cell transplants.

40 able engraftment of allogeneic hematopoietic stem cell transplants.

41 r of immune function to patients who receive stem cell transplants.

42 may reduce the rate of relapse in allogeneic stem cell transplants.

43 constitution in recipients of haploidentical stem-cell transplants.

44 nalidomide), and 76% had received autologous stem-cell transplants.

45 Which patients should receive an allogeneic stem cell transplant?

46 th noncrystalline LCPT, of whom 11 underwent stem cell transplant, 16 received chemotherapy only, and

47 compared with patients who did not receive a stem-cell transplant (42% v 16%).

48 a who had undergone autologous hematopoietic stem-cell transplant 50 to 70 days earlier.

49 ew and examine the data of second allogeneic stem cell transplant after autologous, allogeneic and um

50 could guide migration and differentiation of stem cell transplants after brain injury.

51 nt of myeloablative allogeneic hematopoietic stem cell transplants, airflow obstruction (AFO) remains

52 se starting treatment achieved hematopoietic stem cell transplant (alloHSCT) compared with 46% in the

53 jor complication of allogeneic hematopoietic stem cell transplant (alloHSCT), underscoring the need t

54 ALL) do not appear to require an allogeneic stem cell transplant (alloSCT) if they achieve a good re

55 ving mobilized stem cells all accepted their stem cell transplant and became tolerant to the VCA.

56 Risk-adapted stem cell transplant and consolidation with novel agents

57 opment of new nonmyeloablative hematopoietic stem cell transplant and gene therapy approaches to leuk

58 patients in need of allogeneic hematopoietic stem cell transplant and has recruited millions of volun

59 tients (P = .005 vs allogeneic hematopoietic stem cell transplant and P = .048 vs others).

60 al infections that occur after hematopoietic stem cell transplant and therapies for hematologic malig

61 plant, persons with autologous hematopoietic stem cell transplant and those without graft-versus-host

62 tegies such as unrelated donor hematopoietic stem cell transplant and tyrosine kinase inhibitors into

63 of an additional 300 patients who underwent stem cell transplant and were enrolled on multicentre cl

64 Four of the children received hematopoietic stem cell transplants and all showed poor graft function

65 , and biologic therapy such as hematopoietic stem cell transplants and mesenchymal cell infusions.

66 eived consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients

67 Studies of critically ill, oncologic or stem cell transplant, and solid organ transplant patient

68 sed immunosuppressive drugs, 13 had received stem cell transplants, and 7 were infected with human im

69 e transfusions, bone marrow or hematopoietic stem cell transplants, and experimental pharmacologic ch

70 to those observed from parallel hemopoietic stem cell transplants, and provide a source of progenito

71 ey, liver, bowel, pancreas, heart, lung, and stem-cell transplant, and blood transfusion.

72 Recipients of allogeneic hematopoietic stem cell transplant appear to have the highest risk of

73 icacy for both solid organ and hematopoietic stem cell transplant applications.

74 Autologous bone marrow and stem-cell transplant approaches in lymphoma patients hav

75 in the field of hematology, as hematopoietic stem cell transplants are already commonplace in clinics

76 The majority of allogeneic stem cell transplants are currently undertaken using G-C

77 The role of pulmonary function before stem cell transplant as a potential risk factor for the

78 ositron emission tomography or hematopoietic stem cell transplant as independent prognostic factors f

79 damine-ferumoxytol-positive macrophages into stem cell transplants, as visualized with IVM and histop

80 In addition, pre-autologous stem cell transplant (ASCT) (18)FDG-PET response to SLT

81 5 patients initially treated with autologous stem cell transplant (ASCT) at Mayo Clinic.

82 Utilization of autologous stem cell transplant (ASCT) was similar across all perio

83 des salvage chemotherapy (SC) and autologous stem cell transplant (ASCT).

84 High-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative t

85 refractory myeloma undergoing an autologous stem-cell transplant (ASCT).

86 luding cytarabine, rituximab, and autologous stem-cell transplant (ASCT).

87 -melphalan with low-dose TBI after haplocord stem cell transplant assures good engraftment and leads

88 The addition of an autologous stem cell transplant before cART withdrawal alters viral

89 outcomes of patients who underwent haplocord stem cell transplant between May 2013 and March 2015 and

90 Researchers have demonstrated that stem-cell transplants can survive, migrate, differentiat

91 ion for the use of RIC regimens in all adult stem cell transplant candidates with acute leukemia in r

92 bsequent admissions with a non-hematopoietic stem cell transplant cohort and excluded solid-organ tra

93 ted mortality was 32.9% in non-hematopoietic stem cell transplant cohort, which was similar to autolo

94 her when compared with the non-hematopoietic stem cell transplant cohort.

95 (MR) imaging of donor-matched and mismatched stem cell transplants demonstrated decreased signal inte

96 The use of imatinib before stem cell transplant did not have an effect on mortality

97 Allogeneic stem cell transplants differ from conventional tissue tr

98 CMV-specific CD8+ T cells from the blood of stem cell transplant donors using staining with HLA-pept

99 I, we show that human central nervous system stem cells transplanted either to the neonatal, the adul

100 enced high-dose chemotherapy with autologous stem-cell transplant failure were included.

101 yeloablative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid diffe

102 ion in a patient who received a heterologous stem cell transplant for acquired immunodeficiency syndr

103 t study that examines the role of allogeneic stem cell transplant for adults with acute lymphoblastic

104 sociated with improved outcome to autologous stem cell transplant for NBL.

105 ation provides the benefits of hematopoietic stem cell transplant for nearly all patients who do not

106 old female patient following a hematopoietic stem cell transplant for relapsed acute lymphoblastic le

107 irectly demonstrate the efficacy of myogenic stem cell transplant for treating muscle degenerative di

108 isease (GVHD) after allogeneic hematopoietic stem cell transplant from a human histocompatibility leu

109 A-deficient SCID (ADA-SCID) is hematopoietic stem cell transplant from an HLA-matched sibling donor,

110 ored in a recipient undergoing an allogeneic stem cell transplant from her HLA-matched related donor.

111 et(high) CTLs) in 53/115 CMV IgG(+) patients stem cell transplanted from CMV IgG(+) donors.

112 ifty-two patients who received hematopoietic stem cell transplants from 2004 through 2008 at the Univ

113 HLA-C2 positive recipients of hematopoietic stem cell transplants from 2DS1 positive donors.

114 Allogeneic stem-cell transplant from histocompatible sibling donors

115 ents with AML who had received hematopoietic stem-cell transplants from unrelated donors matched for

116 odysplastic syndrome (MDS) receiving a first stem cell transplant had marrow cells prospectively anal

117 patients with crystalline LCPT treated with stem cell transplant had stable or improved kidney funct

118 n patients with unrelated donor haemopoietic stem-cell transplants had adequate engraftment with acce

119 ents undergoing haploidentical hematopoietic stem cell transplant (haplo-HSCT) without the risk for u

120 Allogeneic hematopoietic stem cell transplant (hazard ratio [HR] = 2.28; 95% conf

121 y results of MVA in allogeneic hematopoietic stem cell transplant (HCT) recipients and Triplex in hea

122 d as a surveillance method for hematopoietic stem cell transplant (HCT) recipients.

123 fields of both solid-organ and hematopoietic stem cell transplant (HCT).

124 with CD4(+) </=200; autologous hematopoietic stem-cell transplant (HCT) or allogeneic-HCT recipients.

125 ed in 3 consecutive cohorts of hematopoietic stem-cell transplant (HCT) recipients (n=2049); cohort 1

126 QOL) and symptom burden during hematopoietic stem-cell transplant (HCT).

127 tcome after high-dose therapy and autologous stem-cell transplant (HDT/ASCT) for patients with relaps

128 herapy and a majority received hematopoietic stem cell transplant (HSCT) (11/13).

129 matched siblings suitable for haematopoietic stem cell transplant (HSCT) are discussed.

130 Autologous hematopoietic stem cell transplant (HSCT) has been effective in treati

131 The field of hematopoietic stem cell transplant (HSCT) has made ground-breaking pro

132 Acute lung injury (ALI) during hematopoietic stem cell transplant (HSCT) is associated with substanti

133 Hematopoietic stem cell transplant (HSCT) is the only cure for sickle

134 Autologous and allogeneic hematopoietic stem cell transplant (HSCT) patients are susceptible to

135 is in the pediatric allogeneic hematopoietic stem cell transplant (HSCT) population is unknown.

136 a CMV-seronegative allogeneic hematopoietic stem cell transplant (HSCT) recipient is generally accep

137 Hematopoietic stem cell transplant (HSCT) recipients admitted to the i

138 galovirus (CMV) viral loads in hematopoietic stem cell transplant (HSCT) recipients are typically mon

139 of adoptive immunotherapy for hematopoietic stem cell transplant (HSCT) recipients or donor vaccinat

140 phase 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who received dono

141 etected in >/=9% of allogeneic hematopoietic stem cell transplant (HSCT) recipients, in whom it can c

142 d mortality in solid organ and hematopoietic stem cell transplant (HSCT) recipients.

143 cal patients and especially in hematopoietic stem cell transplant (HSCT) recipients.

144 to latency and reactivation in hematopoietic stem cell transplant (HSCT) recipients.

145 ty and mortality in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

146 erapy, such as solid organ and hematopoietic stem cell transplant (HSCT) recipients.

147 in patients with leukemia and hematopoietic stem cell transplant (HSCT) recipients.

148 mononuclear cells (PBMCs) from hematopoietic stem cell transplant (HSCT) recipients.

149 lid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients.

150 of infection in azole-treated hematopoietic stem cell transplant (HSCT) recipients.

151 ity, particularly in pediatric hematopoietic stem cell transplant (HSCT) recipients.

152 ed infectious complications in hematopoietic stem cell transplant (HSCT) recipients.

153 patients, including allogeneic hematopoietic stem cell transplant (HSCT) recipients.

154 ed treatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.

155 Hematopoietic stem cell transplant (HSCT)-associated thrombotic microa

156 olid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT).

157 elated or unrelated allogeneic hematopoietic stem cell transplant (HSCT).

158 a double umbilical cord blood hematopoietic stem cell transplant (HSCT).

159 tabilize cerebral disease is a hematopoietic stem cell transplant (HSCT).

160 dystrophy after treatment with hematopoietic stem cell transplant (HSCT).

161 and mortality after allogeneic hematopoietic stem cell transplant (HSCT).

162 are frequent complications of hematopoietic stem cell transplant (HSCT).

163 cular interest in the field of hematopoietic stem cell transplant (HSCT).

164 lable other than myeloablative hematopoietic stem cell transplant (HSCT); however, relapse remains a

165 e infections often occur after hematopoietic stem cell transplant (HSCT); vaccination is important fo

166 tients receiving an allogeneic hematopoietic stem cell transplant (HSCT, 79%) versus those receiving

167 l blood mononuclear cells from hematopoietic stem-cell transplant (HSCT) and solid organ transplant r

168 In five pairs, hematopoietic stem-cell transplant (HSCT) donors were sensitized by ki

169 64 admissions for induction or hematopoietic stem-cell transplant (HSCT) from 2006 to 2014 was select

170 infection in adult allogeneic hematopoietic stem-cell transplant (HSCT) patients.

171 ts, the risk of skin cancer in hematopoietic stem-cell transplant (HSCT) recipients has not been exte

172 n of CMV disease in allogeneic hematopoietic stem-cell transplant (HSCT) recipients.

173 ith a uniform reduced intensity haemopoietic stem-cell transplant (HSCT) regimen for children with no

174 morbidity and mortality after hematopoietic stem cell transplants (HSCTs) are currently under invest

175 integration site analysis in a hematopoietic stem cell-transplanted humanized mouse model.

176 Hematopoietic stem cell transplant, if performed early in metachromati

177 an of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were adminis

178 o was cured following a delta32/delta32 CCR5 stem cell transplant in 2007 revealed no antibodies agai

179 t feasible, then high-dose chemotherapy with stem cell transplant in an experienced center is a reaso

180 salvage chemotherapy followed by autologous stem cell transplant in chemosensitive disease.

181 essment; 25 patients underwent an allogeneic stem cell transplant in first CR and were excluded, leav

182 Allogeneic stem cell transplant in second remission is the only cur

183 rther suggests that the rejection of similar stem cell transplants in humans will be dependent upon t

184 t to allow for the monitoring of therapeutic stem cell transplants in murine dystrophic muscle.

185 KIR/HLA mismatched hematopoietic stem cell transplants induce alloreactive NK cells, whic

186 roanatomical and behavioral effects of human stem cell transplants into the striatum of quinolinic ac

187 So far, brain- and retina-derived stem cells transplanted into adult retina have shown lit

188 We find that neural stem cells transplanted into the brain after neuronal ab

189 ation of human neurospheres derived from CNS stem cells transplanted into the ischemic cortex of rats

190 High-dose chemotherapy with autologous stem cell transplant is associated with long-term, disea

191 The role of allogeneic hematopoietic stem cell transplant is less clear but may be useful in

192 In myelofibrosis, stem cell transplant is the current treatment of choice

193 eukemia-like" regimen followed by allogeneic stem-cell transplant may be advisable; addition of a tyr

194 8%) had received an allogeneic hematopoietic stem cell transplant (median, 61 [interquartile range {I

195 reg-associated chemokine receptors in murine stem cell transplant models.

196 actory Hodgkin lymphoma following autologous stem cell transplant (N = 102) after a median observatio

197 n = 766; HR = 0.66; P = .001) and autologous stem cell transplant (n = 273; HR = 0.55; P = .004) were

198 CI, 2.39-6.07) and autologous hematopoietic stem cell transplant (odds ratio, 1.28; 95% CI, 1.06-1.5

199 spital mortality in allogeneic hematopoietic stem cell transplant (odds ratio, 3.81; 95% CI, 2.39-6.0

200 mphoma who previously received an autologous stem cell transplant or two previous multiagent chemothe

201 as a conditioning regimen for hematopoietic stem-cell transplant or myeloablative doses of radioimmu

202 , the conditioning regimen for hematopoietic stem cell transplant (P = .002), and the cumulative dose

203 mycosis in a nonmyeloablative hematopoietic stem cell transplant patient, we identified a greater-th

204 transplant recipients and one hematopoietic stem-cell transplant patient with positive A. calidoustu

205 We identified all hematologic malignancy and stem cell transplant patients diagnosed with proven muco

206 llowing immune reconstitution, hematopoietic stem cell transplant patients often display reduced immu

207 , we infused 12 haploidentical hematopoietic stem cell transplant patients with increasing numbers of

208 significantly higher than non-hematopoietic stem cell transplant patients.

209 is frequent and often fatal in hematopoietic stem cell transplant patients.

210 rs of myeloablative allogeneic hematopoietic stem cell transplant patients.

211 setting and in solid-organ and hematopoietic stem cell transplant patients.

212 her odds of mortality than non-hematopoietic stem cell transplant patients.

213 cluding patients who received blood-building stem cell transplants, patients with chronic granulomato

214 om 663 unrelated marrow and peripheral blood stem cell transplants performed from 1995 to 2007 for tr

215 Among patients with hematopoietic stem cell transplant, persons with autologous hematopoie

216 lenalidomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of

217 myelodysplastic syndromes, and hematopoietic stem cell transplant populations has been evaluated in r

218 of Legionnaires' disease in a hematopoietic stem cell transplant recipient caused by this organism i

219 9 infection was diagnosed in a hematopoietic stem cell transplant recipient during conditioning regim

220 erococcus faecalis infection in a cord blood stem cell transplant recipient previously treated with l

221 cute liver failure in an adult hematopoietic stem cell transplant recipient.

222 patients, including recipients of allogeneic stem cell transplants, recipient-derived antileukemia va

223 hich was similar to autologous hematopoietic stem cell transplant recipients (30.1%) and those who di

224 Autologous hematopoietic stem cell transplant recipients and those who do not dev

225 Hematopoietic stem cell transplant recipients are more likely to be im

226 Hematopoietic stem cell transplant recipients are more likely to devel

227 After a cluster of fatal toxoplasmosis among stem cell transplant recipients at 2 hospitals, surveill

228 ly 20% of pediatric allogeneic hematopoietic stem cell transplant recipients develop disseminated Ad

229 r subunit knockout mice, we demonstrate that stem cell transplant recipients lacking the ability to g

230 in preventing RSV LRTIs in 50 hematopoietic stem cell transplant recipients or patients with hematol

231 Five hematopoietic stem cell transplant recipients that developed breakthro

232 he effects of GvHD itself, all serve to make stem cell transplant recipients vulnerable to disease fr

233 frequency of severe sepsis in hematopoietic stem cell transplant recipients was five times higher wh

234 Twenty-four hematopoietic stem cell transplant recipients were enrolled sequential

235 nduction therapy or allogeneic hematopoietic stem cell transplant recipients were randomized (1:1 rat

236 reata obtained at autopsy from hematopoietic stem cell transplant recipients who had received their t

237 ve cohort of female allogeneic hematopoietic stem cell transplant recipients who received stem cells

238 rly, in subsequent admissions, hematopoietic stem cell transplant recipients with graft-versus-host d

239 We compared outcomes of hematopoietic stem cell transplant recipients with severe sepsis durin

240 A total of 21,898 hematopoietic stem cell transplant recipients with severe sepsis were

241 ected patients (renal transplant recipients, stem cell transplant recipients, and congenitally infect

242 ant women, neutropenic hosts, solid-organ or stem cell transplant recipients, and patients receiving

243 ime-to-event analysis of 42 CMV-seropositive stem cell transplant recipients, and two of three patien

244 nd poor survival in allogeneic hematopoietic stem cell transplant recipients.

245 f invasive aspergillosis among hematopoietic stem cell transplant recipients.

246 nd viral control in allogeneic hematopoietic stem cell transplant recipients.

247 atological malignancies and in hematopoietic stem cell transplant recipients.

248 management of solid organ and hematopoietic stem cell transplant recipients.

249 eutic strategy for mucormycosis in organ and stem cell transplant recipients.

250 leading cause of mortality in hematopoietic stem cell transplant recipients.

251 mportant cause of morbidity and mortality in stem cell transplant recipients.

252 n causing diarrhea among adult hematopoietic stem cell transplant recipients.

253 mortality of severe sepsis in hematopoietic stem cell transplant recipients.

254 Modification codes to identify hematopoietic stem cell transplant recipients.

255 ansplant recipients (n = 197), 0% to 5.8% in stem-cell transplant recipients (n = 103), and 11.2 to 1

256 One-half of bone-marrow transplant (BMT) and stem-cell transplant recipients have reactivation of lat

257 Allogeneic hematopoietic stem-cell transplant recipients often receive fluconazol

258 ral maribavir in CMV-seropositive allogeneic stem-cell transplant recipients were evaluated in a rand

259 e reconstitution of autologous hematopoietic stem-cell transplant recipients with the progeny of matu

260 recent cohorts of solid-organ and allogeneic stem-cell transplant recipients, respectively.

261 d plasma specimens collected from allogeneic-stem-cell transplant recipients.

262 thy seropositive donors and in hematopoietic stem-cell transplant recipients.

263 ) of the illnesses occurred in hematopoietic stem-cell transplant recipients.

264 e 2b dose-range-finding prophylaxis study in stem-cell transplant recipients.

265 sease (cGVHD) after allogeneic hematopoietic stem cell transplant reflects a complex immune response

266 with JMML relies on allogeneic hematopoietic stem cell transplant, relapse is the most frequent cause

267 atients with platinum-resistant disease, and stem cell transplant remains an area of active study.

268 ion of stem cells from the BM and autologous stem cell transplant rescued RIL in mice.

269 chronic phase chronic myeloid leukemia with stem cell transplant reserved for patients who have dise

270 Hematopoietic stem cell transplant (SCT) is currently the only therapy

271 ine clinical factors, induction therapy, and stem cell transplant (SCT) on the outcomes of 311 patien

272 r prevention and treatment of postallogeneic stem cell transplant (SCT) relapse.

273 The effects of stem cell transplant (SCT) status, underlying disease, a

274 38 CR patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached.

275 se patients who relapse following autologous stem cell transplant (SCT), multiple treatment options a

276 cancer survivors who underwent myeloablative stem cell transplant (SCT).

277 e (p < 0.0001) and not undergoing allogeneic stem cell transplant (SCT, p = 0.0005) predicted poor ov

278 ients that received allogeneic hematopoietic stem cell transplants (SCT) between 1999 and 2002.

279 A total of 304 patients receiving allogeneic stem cell transplants (SCT) were randomized to receive f

280 Stem-cell transplant (SCT) was compared with chemotherap

281 ine whether regulatory T cells in allogeneic stem cell transplants (SCTs) ameliorate GVHD after trans

282 eeding risk in patients receiving allogeneic stem cell transplants (SCTs) or chemotherapy but not in

283 host-reactive donor T cells from allogeneic stem-cell transplants (SCTs) using an anti-CD25 immunoto

284 vious studies of recipients of hematopoietic stem-cell transplants suggest that graft-versus-host dis

285 Hematopoietic stem cell transplant therapy is limited by pulmonary inf

286 in cytotoxic anticancer therapies as well as stem cell transplant therapy.

287 RNAs can be used together with hematopoietic stem cell transplant to stably modulate gene expression

288 RSV-B) outbreak in a hematology-oncology and stem cell transplant unit.

289 Allogeneic hematopoietic stem cell transplant was offered to selected patients in

290 Salvage high-dose chemotherapy plus a stem-cell transplant was required in six (6%) patients i

291 amustine-containing regimen, or haemopoietic stem-cell transplant were also excluded.

292 oma cells > or = 5,000/microL, or history of stem-cell transplant were ineligible.

293 y-one recipients of allogeneic hematopoietic stem cell transplants who underwent GBCA-enhanced MR ima

294 fficient techniques to noninvasively monitor stem cell transplants will accelerate the development of

295 xty-five patients underwent nonmyeloablative stem cell transplant with ATG, TBI 200 cGy, and fludarab

296 skin biopsy in patients who have undergone a stem cell transplant with eruptions on the head and neck

297 sive detection of innate immune responses to stem cell transplants with magnetic resonance (MR) imagi

298 MSCs in vivo and can be used for tracking of stem cell transplants with MR imaging.

299 sive detection of innate immune responses to stem cell transplants with MR imaging.

300 were recipients of allogeneic hematopoietic stem cell transplant, with their infections caused by fi